Mayo Clinic Laboratory and Pathology Research Roundup: Feb. 29

By Kelley Luedke • February 29, 2016

Share this:

The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including a featured article of the week, abstracts, and complete list of published studies and reviews.

Featured Study of the Week

Assay Helps Identify Responsive Patients with Cancer of Unknown Primary for Standard Treatment Therapy 

Carcinoma of unknown primary (CUP) is a rare disease—representing less than five percent of all cancers—in which malignant cancer cells are found in the body, but the place where the cancer began is not known. In an effort to improve treatment options, Mayo Clinic and the North Central Cancer Treatment Group (now the Alliance for Clinical Trials in Oncology) conducted a prospective, phase II trial, combining everolimus, an inhibitor of the mTOR protein, with carboplatin and paclitaxel for CUP patients. The study was published in Annals of Oncology.

Published to PubMed This Week

• Sessile Serrated Polyps are Precursors of Colon Carcinomas Predominantly with Deficient DNA Mismatch Repair
  Clinical Gastroenterology and Hepatology
• C4 Glomerulopathy: A Disease Entity Associated With C4d Deposition
  American Journal of Kidney Diseases
• Prevalence of MYD88 L265P Mutation in Histologically Proven, Diffuse Large B-Cell Vitreoretinal Lymphoma
  Retina
• Safety and Accuracy of Percutaneous Image-Guided Core Biopsy of the Spleen
  American Journal of Roentgenology

Kelley Luedke

Kelley Luedke is a Marketing Channel Manager at Mayo Clinic Laboratories. She is the principle editor and writer of Insights and leads social media and direct marketing strategy. Kelley has worked at Mayo Clinic since 2013. Outside of work, you can find Kelley running, traveling, playing with her kitty, and exploring new foods.